- 2023 Multidisciplinary Oncology Review
- 2022
- Videos
- 2021
- 2020
- 2019
- Hematology & Medical Oncology Review 2019
- 2018
- Events
Playback speed
10 seconds
ASH Update on Moderate-Intensity Chemo for AML: What Are the Remission Rates & OS of AZA/VEN, and LDAC/VEN? Does OS Improve With VEN + Decitabine for TP53 Mutation in AML, and What Are the New Potential Agents?
0 views
March 5, 2021
Comments 0
Login to view comments.
Click here to Login
ASH Review VIRTUAL 2020: Current Updates in Hematologic Diseases